NCT05572879View on ClinicalTrials.gov

A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

2,600

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

June 23, 2023

Study Completion Date

February 9, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

EuCorVac-19

COVID-19 vaccine

BIOLOGICAL

ChAdOx1 nCoV-19

COVID-19 vaccine

Trial Locations (1)

Unknown

Trial site, Manila

Sponsors
All Listed Sponsors
lead

EuBiologics Co.,Ltd

INDUSTRY

NCT05572879 - A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults | Biotech Hunter | Biotech Hunter